Already a Vigil Neuroscience investor, Sanofi has agreed to buy the rest of the biotech’s shares for $8 apiece, representing ...

Sanofi has unveiled plans to invest “at least” $20bn into the US by 2030, with the commitment including a significant ...

AAN conference featured the latest research and developments in neurological disorders like Alzheimer's disease, epilepsy and ...

AB Science SA (Euronext - FR0010557264 - AB) today reports its revenues for the year 2024 and provides an update on its activities. CLINICAL DEVELOPMENT KEY EVENTS DURING THE YEAR 2024 AND SINCE ...

Sanofi's oral BTK inhibitor tolebrutinib is heading towards an FDA decision in September as a potential treatment for multiple sclerosis. The importance of biosimilars only continues to grow ...

PRLs in Tolebrutinib Trials At ACTRIMS, Oh presented a post hoc analysis of PRLs in the phase III trials of the investigational Bruton's tyrosine kinase (BTK) inhibitor tolebrutinib. "We're very ...

A research initiative in multiple sclerosis launched with support from Novartis has partnered with Seqster to provide a unified platform for data sharing, supporting patients with the disease, as ...

and Sanofi's experimental tolebrutinib. "The FDA appears to be focused on confirmed disability worsening endpoints where vidofludimus compares well in the PPMS population," the analysts wrote.

While a four-month progressive resistance training program improved muscle strength in people with secondary progressive multiple sclerosis (SPMS) in the Netherlands, it did not significantly ...

Suggested remit: To appraise the clinical and cost effectiveness of tolebrutinib within its marketing authorisation for treating non-relapsing secondary progressive multiple sclerosis.

Amyotrophic lateral sclerosis (ALS) is a disease that destroys the nerves necessary for movement. About 30,000 people in the United States are affected, and doctors still don't know what causes it.

Ladies and gentlemen, welcome to Roche First Quarter Sales Webinar 2025. My name is Henrik, and I'm the technical operator for today's call. Kindly note that the webinar is being recorded. I’d ...